Therapeutic strategies to combat neointimal hyperplasia in vascular grafts.
Neointimal hyperplasia (NIH) in bypass conduits such as veins and prosthetic grafts is an important clinical entity that limits the long-term success of vascular interventions. Although the development of NIH in the conduits shares many of the same features of NIH that develops in native arteries after injury, vascular grafts are exposed to unique circumstances that predispose them to NIH, including surgical trauma related to vein handling, hemodynamic changes creating areas of low flow, and differences in biocompatibility between the conduit and the host environment. Multiple different approaches, including novel surgical techniques and targeted gene therapies, have been developed to target and prevent the causes of NIH. Recently, the PREVENT trials, the first molecular biology trials in vascular surgery aimed at preventing NIH, have failed to produce improved clinical outcomes, highlighting the incomplete knowledge of the pathways leading to NIH in vascular grafts. In this review, we aim to summarize the pathophysiologic pathways that underlie the formation of NIH in both vein and synthetic grafts and discuss current and potential mechanical and molecular approaches under investigation that may limit NIH in vascular grafts.
Department of Surgery and the Interdepartmental Program in Vascular Biology and Therapeutics, Yale University School of Medicine, New Haven, CT, USA.
Michael J
MJ
Collins
Xin
X
Li
Wei
W
Lv
Chenzi
C
Yang
Clinton D
CD
Protack
Akihito
A
Muto
Caroline C
CC
Jadlowiec
Chang
C
Shu
Alan
A
Dardik
D000818:Animals; D001807:Blood Vessel Prosthesis; D015316:Genetic Therapy / Q000379:methods; D006801:Humans; D006965:Hyperplasia; D058426:Neointima / Q000473:pathology* / Q000517:prevention & control; D058017:Vascular Grafting / Q000379:methods*; D014656:Vascular Surgical Procedures / Q000379:methods; D014680:Veins / Q000473:pathology / Q000637:transplantation*